Michael D Muhlebach
Overview
Explore the profile of Michael D Muhlebach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qu B, Miskey C, Gomer A, Kleinert R, Ibanez S, Eberle R, et al.
Proc Natl Acad Sci U S A
. 2024 May;
121(23):e2407437121.
PMID: 38814864
The accessory protease transmembrane protease serine 2 (TMPRSS2) enhances severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uptake into ACE2-expressing cells, although how increased entry impacts downstream viral and host processes...
2.
Galy A, Berkhout B, Breckpot K, Pichon C, Bloom K, Kiem H, et al.
Hum Gene Ther
. 2023 Aug;
34(17-18):896-904.
PMID: 37639360
The development of prophylatic or therapeutic medicines for infectious diseases is one of the priorities for health organizations worldwide. Innovative solutions are required to achieve effective, safe, and accessible treatments...
3.
Nouailles G, Adler J, Pennitz P, Peidli S, Teixeira Alves L, Baumgardt M, et al.
Nat Microbiol
. 2023 Apr;
8(5):860-874.
PMID: 37012419
Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to...
4.
Horner C, Fiedler A, Bodmer B, Walz L, Scheuplein V, Hutzler S, et al.
NPJ Vaccines
. 2023 Mar;
8(1):46.
PMID: 36964176
A novel Influenza A virus (subtype H7N9) emerged in spring 2013 and caused considerable mortality in zoonotically infected patients. To be prepared for potential pandemics, broadly effective and safe vaccines...
5.
Auste A, Muhlebach M
J Gen Virol
. 2023 Feb;
103(11).
PMID: 36748683
The generation of recombinant measles virus (MeV) from manipulated genomes on plasmid DNA is quite a complex and inefficient process. As a member of the order its single-stranded ssRNA genome...
6.
Pennitz P, Goekeri C, Trimpert J, Wyler E, Ebenig A, Weissfuss C, et al.
STAR Protoc
. 2022 Dec;
4(1):101957.
PMID: 36542521
In infectious disease research, single-cell RNA sequencing allows dissection of host-pathogen interactions. As a prerequisite, we provide a protocol to transform solid and complex organs such as lungs into representative...
7.
Ebenig A, Lange M, Muhlebach M
NPJ Vaccines
. 2022 Oct;
7(1):119.
PMID: 36243743
Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The...
8.
Ebenig A, Muraleedharan S, Kazmierski J, Todt D, Auste A, Anzaghe M, et al.
Cell Rep
. 2022 Aug;
40(7):111214.
PMID: 35952673
Vaccine-associated enhanced respiratory disease (VAERD) is a severe complication for some respiratory infections. To investigate the potential for VAERD induction in coronavirus disease 2019 (COVID-19), we evaluate two vaccine leads...
9.
Nettelbeck D, Leber M, Altomonte J, Angelova A, Beil J, Berchtold S, et al.
Viruses
. 2021 Aug;
13(8).
PMID: 34452286
Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction...
10.
Henss L, Auste A, Schurmann C, Schmidt C, von Rhein C, Muhlebach M, et al.
J Gen Virol
. 2021 Apr;
102(4).
PMID: 33830908
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has caused a pandemic with tens of millions of cases and more than a million deaths. The infection causes COVID-19, a disease...